Second-line chemotherapy in metastatic docetaxel-resistant prostate cancer: A review

Medical Oncology

Volumn 29, Issue 2, 2012, Pages 776-785

  Colloca, Giuseppe ^a   Venturino, Antonella ^a   Checcaglini, Franco ^b  

^a Giovanni Borea Hospital   (Italy)

^b ASL 1 Umbria   (Italy)

Author keywords

Castration resistance; Chemotherapy; Docetaxel; Prostate cancer

Indexed keywords

CABAZITAXEL; DOCETAXEL; MITOXANTRONE; PACLITAXEL; PREDNISONE; SATRAPLATIN; ANTINEOPLASTIC AGENT; TAXOID;

ANEMIA; CASTRATION RESISTANT PROSTATE CANCER; CYTOTOXICITY; DIARRHEA; DRUG RESISTANCE; DRUG WITHDRAWAL; HORMONE SENSITIVITY; HUMAN; MALE; METASTASIS; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; REVIEW; DRUG EFFECT; PROSTATE TUMOR; SALVAGE THERAPY;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; PROSTATIC NEOPLASMS; SALVAGE THERAPY; TAXOIDS;

EID: 84866295878     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-011-9855-6     Document Type: Review

References (90)

1. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 2010;46:765-81.
2. Tannock IF, Osoba D, Stockler MR, Scott Ernst D, Neville AJ, Moore MJ, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol. 1996;14:1756-64.
3. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al., for the TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502-1512.
4. Petrylak DP, Tangen CM, Hussain MH, Lara PN, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513-20.
5. Holzbeierlein J, Lal P, La Tulippe E, Smith A, Satagopan J, Zhang L, et al. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol. 2004;164:217-27.
6. Colloca G, Venturino A, Checcaglini F. Localized androgenindependent prostate cancer. Cancer Ther. 2007;5:485-500.
7. Taplin ME, Rajeshkumar B, Halabi S, Werner CP, Woda BA, Picus J, et al. Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B study 9663. J Clin Oncol. 2003;21:2673-8.
8. Kelly WK, Scher HI, Mazumdar M, Vlamis V, Schwartz M, Fossa SD. Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. J Clin Oncol. 1993;11(4):607-15.
9. Hodgson MC, Astapova I, Cheng S, Lee LJ, Verhoeven MC, Choi E, et al. The androgen receptor recruits nuclear receptor CoRepressor (N-CoR) in the presence of mifepristone via its N and C termini revealing a novel molecular mechanism for androgen receptor antagonists. J Biol Chem. 2005;280:6511-9.
10. Small EJ, Halabi S, Dawson NA, Stadler WM, Rini BI, Picus J, et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol. 2004;22:1025-33.
11. Mostaghel EA, Montgomery B, Nelson PS. Castration-resistant prostate cancer: targeting androgen metabolic pathways in recurrent disease. Urol Oncol. 2009;27:251-7.
12. Best CJM, Gillespie JW, Yi Y, Chandramouli GVR, Perlmutter MA, Gathright Y, et al. Molecular alterations in primary prostate cancer after androgen ablation therapy. Clin Cancer Res. 2005;11: 6823-34.
13. Morgenbesser SD, McLaren RP, Richards B, Zhang M, Akmaev VR, Winter SF, et al. Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model. Prostate. 2007;67:83-106.
14. Hsieh AC, Small EJ, Ryan CJ. Androgen-response elements in hormone-refractory prostate cancer: implications for treatment development. Lancet Oncol. 2007;8:933-9.
15. Mathew P, DiPaola R. Taxane refractory prostate cancer. J Urol. 2007;178:S36-41.
16. Beekman KW, Fleming MT, Scher HI, Slovin SF, Ishill NM, Heller G, et al. Second-line chemotherapy for prostate cancer: patient characteristics and survival. Clin Prostate Cancer. 2005;4(2): 86-90.
17. Yonemori K, Katsumata N, Uno H, Matsumoto K, Kouno T, Tokunaga S, et al. Efficacy of weekly paclitaxel in patients with docetaxel-resistant breast cancer. Breast Cancer Res Treat. 2005;89: 237-41.
18. Di Lorenzo G, Buonerba C, Faiella A, Rescigno P, Rizzo M, Autorino R, et al. Phase II study of docetaxel re-treatment in docetaxel-pretreated castration-resistant prostate cancer. BJU Int. 2010, June 29 [Epub ahead of print].
19. Urakami S, Yoshino T, Kikuno N, Imai SH, Yoneda T, Kishi H, et al. Docetaxel-based chemotherapy as second-line treatment for paclitaxel-based chemotherapy-resistant hormone-refractory prostate cancer: a pilot study. Urology. 2005;65:543-8.
20. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, et al., for the TROPIC Investigators. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet Oncol 2010;376:1147-1154.
21. Gleave M, Miyake H, Chi K. Beyond simple castration: targeting the molecular basis of treatment resistance in advanced prostate cancer. Cancer Chemother Pharmacol. 2005;56:s47-57.
22. Hussain M, Tangen CM, Higano C, Schelhammer PF, Faulkner J, Crawford ED, et al. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer; data from Southwest Oncology Group trial 9346 (INT-0162). J Clin Oncol. 2006;24:3984-90.
23. Taylor CD, Elson P, Trump DL. Importance of continued testicular suppression in hormone-refractory prostate cancer. J Clin Oncol. 1993;11:2167-72.
24. Hussain M, Wolf M, Marshall E, Crawford ED, Eisenberger M. Effects of continued androgen-deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer: a Southwest Oncology Group report. J Clin Oncol. 1994;12:1868-75.
25. Aragon-Ching JB, Dahut WL. Chemotherapy in androgen-independent prostate cancer (AIPC): what's next after taxane progression? Cancer Ther. 2007;5:151-60.
26. Sternberg CN, Petrylak DP, Sartor O, Witjes JA, Demkow T, Ferrero JM, et al. Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. J Clin Oncol. 2009;27:5431-8.
27. Rosenberg JE, Weinberg VK, Kelly WK, Michaelson D, Hussain MH, Wilding G, et al. Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients. Randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Cancer. 2007;110:556-63.
28. Fleming MT, Kolodziej MA, Awasthi S, Hutson TE, Martincic D, Sonpavde G, et al. Results of a randomized phase II study of mitoxantrone versus mitoxantrone with cetuximab in metastatic castrate-resistant prostate cancer (CRPC) previously treated with docetaxel-based chemotherapy. J Clin Oncol. 2010;28(15S): 355S.
29. Berger ER, Ciuleanu T, Hart L, Chi KN, Alexandre J, Oudard S, et al. Result of a randomized phase II study of irofulven in hormone- refractory prostate cancer patients that have failed first-line docetaxel treatment. J Clin Oncol. 2007;25(18S):251s.
30. de Bono JS, Fizazi K, Flechon A, Heidenreich A, Voog E, Davis NB, et al. Randomized phase II study of CNTO 328 (C), an anti- IL-6 monoclonal antibody, in combination with mitoxantrone (M) versus M alone in metastatic castration-resistant prostate cancer (CRPC). In: Proc genitourinary cancers symposium, poster session (abstract no. 86). 2010.
31. Saad F, Hotte SJ, North SA, Eigl BJ, Chi KN, Czaykowski P, et al. A phase II randomized study of custirsen (OGX-011) combination therapy in patients with poor-risk hormone refractory prostate cancer (HRPC) who relapsed on or within six months of 1st-line docetaxel therapy. J Clin Oncol. 2008;26(15S): 250s.
32. Ross RW, Beer TM, Jacobus S, Bubley GJ, Taplin ME, Ryan CW, et al., for the Prostate Cancer Clinical Trials Consortium. A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel. Cancer. 2008;112:521-526.
33. Nakabayashi M, Sartor O, Jacobus S, Regan MM, McKearn D, Ross RW, et al. Response to docetaxel/carboplatin-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer. BJU Int. 2008; 101:308-12.
34. Reuter CW, Morgan MA, Ivanyi P, Fenner M, Ganser A, Gruenwald V. Carboplatin plus weekly docetaxel as salvage chemotherapy in docetaxel-resistant and castration-resistant prostate cancer. World J Urol. 2010;28:391-8.
35. Chatta GS, Feinstein TM, Appleman LJ, Friedland DM, Jacobs SA, Evans TL, et al. Oxaliplatin and docetaxel in castrationresistant prostate cancer (CRPC) patients treated with up to two prior chemotherapeutic regimens: updated results of a phase II trial. J Clin Oncol. 2008;26(15S):286s.
36. Caffo O, Sava T, Comploj E, Giampaolo MA, Segati R, Valduga F, et al. Estramustine plus docetaxel as second-line therapy in patients with hormone-refractory prostate cancer resistant to docetaxel alone. Urol Oncol. 2010;28:152-6.
37. Di Lorenzo G, Figg WD, Fossa SD, Mirone V, Autorino R, Longo N, et al. Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study. Eur Urol. 2008;54(5):1089-94.
38. Epplen R, Pfister DJ, Thuer D, Brehmer B, Heidenreich A. The combination of docetaxel and bevacizumab as a second-line therapy in patients with HRPCA and PSA relapse. In: Proc genitourinary cancers symposium, poster session (abstract no. 97). 2010.
39. Heidenreich A, Pfister DA, Thuer D, Epplen R, Firek P, Brehmer B. Docetaxel rechallenge versus docetaxel/bevacizumab in castration- resistant prostate cancer following first-line docetaxel. In: Proc genitourinary cancers symposium, poster session (abstract no. 178). 2010.
40. Petrioli R, Pascucci A, Francini E, Marsili S, Sciandivasci A, De Rubertis G, et al. Weekly high-dose calcitriol and docetaxel in patients with metastatic hormone-refractory prostate cancer previously exposed to docetaxel. BJU Int. 2007;100(4):775-9.
41. Poiesz B, Reeves J, McNulty W, Maleski J, Holmlund J, Leopold L. Preliminary report of an open-label, multicenter, phase I/II study of AT-101 in combination with docetaxel and prednisone in men with docetaxel refractory prostate cancer. J Clin Oncol. 2009; 27(15S):270s.
42. Cathomas R, Rothermundt C, van Moos R, Betticher DC, Winterhalder RC, Droege C, et al. Cetuximab in combination with docetaxel in patients with metastatic castration-resistant and docetaxel-refractory prostate cancer: a multicenter phase II trial (SAKK 08/07). J Clin Oncol. 2010;28(15S):383s.
43. Sella A, Yarom N, Zismas A, Kovel S. Paclitaxel, estramustine and carboplatin combination chemotherapy after initial docetaxel-based chemotherapy in castration-resistant prostate cancer. Oncology. 2009;76(6):442-6.
44. Beer TM, Ryan C, Alumkal J, Ryan CW, Sun J, Eilers KM. A phase II study of paclitaxel poliglumex in combination with transdermal estradiol for the treatment of metastatic castrationresistant prostate cancer after docetaxel chemotherapy. Anticancer Drugs. 2010;21(4):433-8.
45. Wilding G, Chen Y, DiPaola RP, Carducci MA, Liu G. E3803: updated results on phase II study of a weekly schedule of BMS- 247550 for patients with castrate refractory prostate cancer (CRPC). J Clin Oncol. 2008;26(15S):267s.
46. Beardsley EK, Saad F, Eigl B, Venner P, Hotte S, Winquist E, Ko YJ, et al. A phase II study of patupilone in patients with metastatic castration-resistant prostate cancer (CRPC) who have progressed after docetaxel. J Clin Oncol. 2009;27(15S):268s.
47. Hussain A, DiPaola RS, Baron AD, Higano CS, Tchekmedyian NS, Johri AR. Phase II trial of weekly patupilone in patients with castration-resistant prostate cancer. Ann Oncol. 2009;20:492-7.
48. Stein MN, Chen Y, Hudes GR, Carducci MA, Tan W, DiPaola RS. ECOG 5805: a phase II study of eribulin mesilate (E7389) in patients with metastatic castration-resistant prostate cancer. J Clin Oncol. 2010;28(15S):355s.
49. de Bono JS, Maroto P, Calvo E, Sonpavde G, Cartwright TH, Loesch D, et al. Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer (CRPC) stratified by prior taxane therapy. In: Proc genitourinary cancers symposium, poster session (abstract no. 166). 2009.
50. Nakabayashi M, Ling J, Xie W, Regan MM, Oh WK. Response to vinorelbine with or without estramustine as second-line chemotherapy in patients with hormone-refractory prostate cancer. Cancer J. 2007;13(2):125-9.
51. Oh WK, Manola J, Babcic V, Harnam N, Kantoff PW. Response to second-line chemotherapy in patients with hormone refractory prostate cancer receiving two sequences of mitoxantrone and taxanes. Urology. 2006;67:1235-40.
52. Morales R, Valverde C, Suarez C, Brana I, Planas J, Padros O, et al. Mitoxantrone as second-line chemotherapy in patients with castrate- resistant prostate cancer (CRPC). Ann Oncol 2010;21(S8): viii 301.
53. Berthold DR, Pond GR, de Wit R, Eisenberger M, Tannock IF, on behalf of the TAX 327 investigators. Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa. Ann Oncol 2008;19: 1749-1753.
54. Michels J, Montemurro T, Murray N, Kollmannsberger C, Chi NK. First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer: does sequence matter? Cancer. 2006;106(5):1041-6.
55. Small E, Harzstark A, Weinberg VK, Smith DC, Mathew P, Beer T, et al. Ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer refractory to docetaxel-based therapy: a phase II study of the DOD Prostate Cancer Clinical Trials Consortium. J Clin Oncol. 2009;27(15S): 248s.
56. Lainakis G, Nikos A, Gerassimos A, Michael C, Iraklis M, Konstantinos L, et al. Biweekly doxorubicin/ketoconazole as second-line treatment in docetaxel-resistant, hormone-refractory prostate cancer. Urology. 2008;71:1181-5.
57. Montanari M, Fabbri F, Frassineti L, Rondini E, Mattioli R, Luzi Fedeli S, et al. Phase II trial of nonpegylated liposomal doxorubicin and low-dose prednisone in second-line chemotherapy for hormone-refractory prostate cancer: a translational study. J Clin Oncol. 2010;28(15S):387s.
58. Kasimis B, Chang VT, Zhong F, Gonzalez ML, Srinivas S, Cogswell J, et al. A second-line trial of epirubicin, estramustine phosphate, and high-dose celecoxib for patients with hormoneresistant prostate cancer. In: Proc genitourinary cancers symposium, poster session (abstract no. 89). 2010.
59. Latif T, Wood L, Connell C, Smith DC, Vaughn D, Lebwohl D, et al. Phase II study of oral bis (aceto) ammine dichloro (cycloexamine) platinum (IV) (JM-216, BMS-182751) given daily x 5 in hormone refractory prostate cancer (HRPC). Investig New Drugs. 2005;23:79-84.
60. Vaishampayan UN, Heilbrun LK, Dickow B, Heath EI, Smith D, Baranowski K, et al. Phase II trial of combination therapy with intravenous bevacizumab, oral satraplatin, and prednisone in docetaxel-pretreated metastatic castration-resistant prostate cancer. In: Proc genitourinary cancers symposium, poster session (abstract no. 208). 2010.
61. Loriot Y, Massard C, Gross-Goupil M, Di Palma M, Escudier B, Bossi A, et al. Combining carboplatin and etoposide in docetaxelpretreated patients with castration-resistant prostate cancer: a prospective study evaluating also neuroendocrine features. Ann Oncol. 2009;20:703-8.
62. Dorff TB, Groshen SG, Wei D, Korn C, Goldkorn A, Quinn DI, et al. Interim results of a phase II trial of pemetrexed, oxaliplatin as 2nd/3rd line therapy in hormone refractory prostate cancer. J Clin Oncol. 2008;26:284s.
63. Blesa JM, Marco VG, Giner-Bosch V, Cerezuela P, Candel VA. Phase II trial of oxaliplatin and capecitabine after progression to first-line chemotherapy in androgen-independent prostate cancer patients. Am J Clin Oncol. 2010, June 9 [Epub ahead of print].
64. Ladoire S, Eymard JC, Zanetta S, Mignot G, Martin E, Kermarrec I, et al. Metronomic oral cyclophosphamide-prednisone chemotherapy is an effective treatment for metastatic hormone-refractory prostate cancer after docetaxel failure. Anticancer Res. 2010;30(10):4317-23.
65. Nelius T, Klatte T, de Riese W, Haynes A, Filleur S. Clinical outcome of patients with docetaxel-resistant hormone-refractory prostate cancer treated with second-line cyclophosphamide-based metronomic chemotherapy. Med Oncol. 2010;27(2):363-7.
66. Fontana A, Galli L, Fioravanti A, Orlandi P, Galli C, Landi L, et al. Clinical and pharmacodynamic evaluation of metronomic cyclophosphamide, celecoxib, and dexamethasone in advanced hormone-refractory prostate cancer. Clin Cancer Res. 2009;15(15): 4954-62.
67. Michaelson D, Bellmunt J, Lewis N, Goel S, Lee RJ, Kaufman DS, et al. Phase II study of trabectedin in men with castration resistant prostate cancer. In: Proc genitourinary cancers symposium, poster session (abstract no. 175). 2009.
68. Hahn NM, Zon RT, Yu M, Ademuyiwa FO, Jones T, Dugan W, et al. A phase II study of pemetrexed as second-line chemotherapy for the treatment of metastatic castrate-resistant prostate cancer (CRPC); Hoosier Oncology Group GUO3-67. Ann Oncol. 2009;20:1971-6.
69. Caffo O, Fratino L, Perin A, Barbieri R, Sava T, Segati R, et al. Pemetrexed in castration-resistant prostate cancer (CRPC) patients resistant to docetaxel: results of a multicentric phase II study. In: Proc genitourinary cancers symposium, poster session (abstract no. 98). 2010.
70. Di Lorenzo G, Autorino R, Giuliano M, Morelli E, Giordano A, Napodano A, et al. Phase II trial of gemcitabine, prednisone, and zoledronic acid in pretreated patients with hormone refractory prostate cancer. Urology. 2007;69:347-51.
71. Jankovic B, Beardsley E, Chi KN. Rechallenge with docetaxel as second-line chemotherapy in patients with metastatic hormone refractory prostate cancer after previous docetaxel: a population based analysis. In: Proc genitourinary cancers symposium, poster session (abstract no. 196). 2010.
72. Ansari J, Choo B, Hussain SA, Zarkar A, Ansari A, Tanguay JS, et al. Docetaxel retreatment as second- and third-line chemotherapy in metastatic hormone refractory prostate cancer patients pretreated with docetaxel: an updated analysis. In: Proc genitourinary cancers symposium, poster session (abstract no. 185). 2009.
73. Loriot Y, Massard C, Gross-Goupil M, Di Palma M, Escudier B, Bossi A, et al. The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer. Eur J Cancer. 2010;46:1770-2.
74. Firek P, Pfister DA, Thuer D, Brehmen B, Epplen R, Heidenreich A. Docetaxel rechallenge at PSA relapse after docetaxel chemotherapy at hormone refractory prostate cancer. In: Proc genitourinary cancers symposium, poster session (abstract no. 93). 2010.
75. Eymard JC, Oudard S, Gravis G, Ferrero JM, Theodore C, Joly F, et al. Docetaxel reintroduction in patients with metastatic castration- resistant docetaxel-sensitive prostate cancer: a retrospective multicentre study. BJU Int. 2010;106(7):974-8.
76. Gernone A, Troccoli G, Pagliarulo V, Pagliarulo A. Retreatment with docetaxel in metastatic castration-resistant prostate cancer. In: Proc genitourinary cancers symposium, poster session (abstract no. 143). 2010.
77. Beer TM, Garzotto M, Henner WD, Eilers KM, Wersinger EM. Intermittent chemotherapy in metastatic androgen-independent prostate cancer. Br J Cancer. 2003;89:968-70.
78. Beer TM, Ryan CW, Venner PM, Petrylak DP, Chatta GS, Ruether JD, et al., ASCENT Investigators. Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer: results from ASCENT, a double-blinded randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxel. Cancer 2008;112(1):326-330.
79. Cabrespine A, Guy L, Khenifar E, Curè H, Fleury J, Penault- Llorca F, et al. Randomized phase II study comparing paclitaxel and carboplatin versus mitoxantrone in patients with hormonerefractory prostate cancer. Urology. 2006;67(2):354-9.
80. Fontana A, Bocci G, Galli L, D'Arcangelo M, Derosa L, Fioravanti A, et al. Metronomic cyclophosphamide in elderly patients with advanced, castration-resistant prostate cancer. J Am Geriatr Soc. 2010;58:986-8.
81. Armstrong AJ, George DJ. Optimizing the use of docetaxel in men with castration-resistant metastatic prostate cancer. Prostate Cancer Prostatic Dis. 2010;13:108-16.
82. Armstrong AJ, Garrett-Mayer E, de Wit R, Tannock I, Eisenberger M. Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer. Clin Cancer Res. 2010;16(1):203-11.
83. Danila DC, Morris MJ, de Bono JS, Ryan CJ, Denmeade SR, Smith MR, et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration- resistant prostate cancer. J Clin Oncol. 2010;28:1496-501.
84. Nakabayashi M, Oh WK, Jacobus S, Regan MM, Taplin ME, Kantoff PW, et al. Activity of ketoconazole after taxane-based chemotherapy in castration-resistant prostate cancer. BJU Int. 2010;105(10):132-9.
85. Shamash J, Davies A, Ansell W, Mcfaul S, Wilson P, Oliver T, et al. A phase II study investigating the re-induction of endocrine sensitivity following chemotherapy in androgen-independent prostate cancer. Br J Cancer. 2008;98:22-4.
86. Van Allen EM, Ryan CJ. Novel secondary hormonal therapy in advanced prostate cancer: an update. Curr Opin Urol. 2009;19(3): 315-21.
87. Bonkhoff H, Berges R. The evolving role of oestrogens and their receptors in the development and progression of prostate cancer. Eur Urol. 2009;55:533-42.
88. Yoshino T, Shiina H, Urakami S, Kikuno N, Yoneda T, Shigeno K, et al. Bcl-2 expression as a predictive marker of hormonerefractory prostate cancer treated with taxane-based chemotherapy. Clin Cancer Res. 2006;12(20):6116-24.
89. George DJ, Halabi S, Shepard TF, Vogelzang NJ, Hayes DF, Small EJ, et al.; Cancer and Leukemia Group B 9480. Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin Cancer Res 2001;7(7):1932-1936.
90. Araujo J, Armstrong AJ, Braud EL, Posadas E, Lonberg M, Gallick GE, et al. Dasatinib and docetaxel combination treatment for patients with castration-resistant progressive prostate cancer: a phase I/II study. J Clin Oncol. 2009;27(15S):249s.